Nasus Pharma Ltd. (NSRX)

Nasus Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	2.68	0.74	0.58	0.93
Research & Development	2.23	0.34	0.57	1.12
Operating Expenses	4.9	1.08	1.15	2.04
Operating Income	-4.9	-1.08	-1.15	-2.04
Interest Expense	-	-0.03	-0.05	-0.02
Interest & Investment Income	0.08	-	-	-
Other Non Operating Income (Expenses)	-0.03	-0	-0.03	-0
EBT Excluding Unusual Items	-4.85	-1.11	-1.22	-2.06
Gain (Loss) on Sale of Investments	-0.95	-0.44	0.22	-0.09
Pretax Income	-5.81	-1.55	-1.01	-2.15
Earnings From Continuing Operations	-5.81	-1.55	-1.01	-2.15
Earnings From Discontinued Operations	-0.05	0.02	-0.05	0.44
Net Income	-5.86	-1.53	-1.05	-1.71
Net Income to Common	-5.86	-1.53	-1.05	-1.71
Shares Outstanding (Basic)	8	7	7	7
Shares Outstanding (Diluted)	8	7	7	7
Shares Change (YoY)	13.98%	-0.43%	2.44%	-
EPS (Basic)	-0.73	-0.22	-0.15	-0.25
EPS (Diluted)	-0.73	-0.22	-0.20	-0.25
Free Cash Flow	-4.93	-0.67	-1.03	-1.21
Free Cash Flow Per Share	-0.62	-0.10	-0.15	-0.18
EBIT	-4.9	-1.08	-1.15	-2.04

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q